thank Brad. you Great,
ahead with focusing the highlight achieved Let since significant beginning we go manufacturing what me and and now the progress have across Pompe on year important activities. program of [indiscernible] our clinical regulatory the
multiple And and five ambulatory X, who patients ventilator are patients chair disease. from received full approved by the excited Cohort enrolled who we results on with are Cohort the demonstrated patients, the the any all all switch Cohort key also at extension and ERT XX begin X four real replacement biomarkers reiterating on program. are additional of care. World data from switch patients of Those positive patients cohort about ambulatory in included all on positive these have standard and muscle this The time first the to effect three ERT patients measures me include disease. therapy. who These in Let we included X never strength February of program nearly who for leaving of nine had care. of Meeting standard of XX so for XX are from adults this and support across Pompe bound reported study overwhelmingly including in enzyme why the months
have to on investigators published our seen magnitude XX with this study improvements We importantly, of strength seeing responses receive meaningful an literature as many persistent improvements of data uniformly are actually been have these XX continue of experts, response. More the further with overtime. patients over extension Pompe not positive and such of many global And our consistency show today, in in the are The across study. sites these data. all AT-GAA patients whom clinically
look year this from mark study April, this patients and this all coming at fall. the two very forward further major In fact study a data we on patient first to scientific reviewing just meeting treatment enrolled XX releasing for extension in crossed in and
these in engaged study us forward as full registration made to FDA. today’s update as as discussions Medicines Building To and is we this responsibility thus there manufacturing turn been far initial quickly these person activities Slide include so ten as as as year focused and on that best Phase At-GAA quarter on on the Since formal define Our series I Europe for XX our great clinical directed the have of on will well our both data well data from as AT-GAA. Pompe first The last activities a X in program possible. key with activities provide set On rather pivotal with to provided the progress next to scheduled And well to we ongoing now available interactions interactions agencies. feedback. initial regulatory ongoing are patients and pathway surrounding been advance many have that XX, is key the have as all approval, the Slide program generation on that cascaded me call, as help fastest so, listed have studies, in both valuable fourth for an discussions interactions let activities. U.S. regulatory will study of European from the with are Agency, EMA, for these regulator of do in XXXX. meetings and we extension
in full we the see occur FDA. from third we update scheduled goal on provide meeting these meetings to XXXX FDA twofold, supplemental alignment the an to formal quarter study in and C interactions press patients. we an European other of we the results of in advice release is include of provide on pursuing with this issued from the ongoing advice mentioned expect this we update morning, with Medicines meeting EMA Agency, formal in to with gain expect interactions minutes Pompe well will are the As design program this a on the after series and for quarter approval our meeting the U.S. in a seek scientific In pivotal end XQ scientific this XXXX The studies first of the quarter. second scheduled type and second of the is written by as that of to agencies the quarter, as
the primary pivotal expect key duration of We with study have alignment Pompe gaining switching ambulatory analysis ERT, involving be this on ERT regulatory study study. from already a these currently We the plan. patients for will adults EMA begun approved design in FDA well expect on non-interventional overall patients on a as the study study we pivotal to roll and the seek which endpoint, endpoint and alignment as statistical secondary we into
success high we may have study to likelihood has this of approval, time very pathway believe of short a period of number reasonable the be and patients. proposed a we a that in with design pivotal As ultimately a relatively
more study regulatory regulatory expect pivotal begin agreement design provide will this is the the of second to we alignment. study in on half the year. With there pivotal We once detail
We supportive to further that commence, well patients. studies in also in smaller studies plan have pediatric as including study populations ERT we naïve as
scale and product success shortly. few studies moments, we bioreactor the XXXXL significant the larger quantity As in available a have Brad we great further have drug at will of had note very will for
preliminary patients set address The grounded of compelling data and that current EMA that seem community the and the FDA newer options Pompe treatment we today. an is disease. it in in their needs desperately Despite that very as interactions patients need the Pompe unmet the to die and soon goal as better functional both and the therapy, many second market and ultimately decline available to demonstrates possible. the safety notion with with believe continues data medical from and is Pompe
we States. that and may discuss pathway to United approval approval regulators, Europe an includes with accelerated a in in or a an As have such, obligation whether conditional we pursue the
Pompe to have faster, in build paths continue while of We these in world's simultaneously to robust many meetings engaging engaged data expected clinical to-date, been in the are possible. sets have the to participate to and the these disease with compelling the experts been ahead. regulatory us most process also preliminary by Several to Pompe studies consider in of experts leading encouraged patients, regulatory
also further need unmet designs patients have continued been sharing input of of and the on support we their the the We of encouraged of their the level extent by with have certainly the our the studies welcomed the in into regulators. perspective and
conditional are that the compelling successful based soon a time. may this our data, accelerated sufficient not that available accelerated or hope we while regulators we at currently ultimately consideration current pathways conditional defining conclude to or in on is While justify approval data
additional to the For to approved well data the our data patients part from be extension path on X the currently history In or into example, to as and approval will from be additional on we as well ERT Phase the support may being data important Pompe further provide will as of need accelerated ongoing these studies, conditional regulatory submissions. any collected addition pathways. as any data study patients of of new natural
paths not meetings are advances upcoming program as (Ph) as of include further outcome continue discussions here series data we that to of will these believe we as the Importantly, regulators event, collected. evolving binary the do and a with do [different] regulatory additional the
And endeavor data has hope we Since to just delivered to through can. as AT-GAA [indiscernible] that and these with development able will people body new living be do just remains promising disease as also ahead. again we we it the that initiated create of to we that's the regulatory as commitment this treatment we Pompe to designate quickly interactions, always Our Pompe been. and as same our many of
clinical Turning Slide now the currently XX, briefly to will I of some review activities key underway.
clinical They our announcing Doing to Cohort a double to data are as this patients Data morning new who Pompe whom now We up will four patients we pulmonary designated enrolled of switch to ERT had that for enrolling are we first population. are of will those ambulatory X ERT likely including of that Phase The previously X, Phase patients. study at but include experience are patients currently XX [indiscernible] and have are the patients current similar additional material. this bioreactor GMP Cohort number the allow assessment a we additional from ambulatory now of XX patients X. in XX manufacturing this XX major XXXL First on expanding to up meeting. the success patients are X this the in study. to months data the availability patients patients XXXX all scale These and to biomarker that on X/X strength of again, underway. additional in Cohort in indicated ongoing enrollment to total six of with Cohort at X/X the expected continued ten muscle evaluation half assessment, based scientific us
these chaperone. is the to will kilogram we dosing. milligram be of dose begin high study This dose the consistent with Importantly, plus ERT, optimal at what per the XX patient our believe
part activities. key of one our that’s So,
the XXX X/X of are we Pompe we patients in have study. Pom-XXX to AT-GAA that retrospective up seen we Pompe as thus in the help for advancing study Study provide natural ERT treated Phase context refer history results on Secondly, to to clinical a our far what disease our
to-date, in and that centers data of half disease Pompe data have XXXX. worldwide second we significant in from collected share the We to expect excellence key of
safety durability as serve study Study running Pom-XXX a care a registration patients X/X outcome also plan intend we also assess fall to observational in to hope later pivotal meeting XXXX. are likely present of half expected the potential see ERT. of as a a Phase the this currently again XX and consistency functional standard prospective at we clinical second study we observational year, and run-in science to to effect. continued this to in from where we study which to with in of or treated the STRIDE We Third, month refer or study And the for data study start
tremendously of is drug to critically studies, in note product had XXXXL By supply doing be gives manufacturing it have program, novel greatly product. So this more in which team to am clinical of AT-GAA this from having as as I a of mentioned, as and also us Biologics. is well as I that tech so by enough a ops our this year our while I the characteristics many advances success commercial importance now here the our great to our team, scale successfully of and technical our Enrique the patients ERT. Amicus overstate Pompe it our major team de-risks to manufacturing led I larger XXXL flexibility timeline Amicus scale, to ERT Diloné quality and ultimately maintaining commercial the this now cannot scale, our scaled it be at will the achievement. proud and we WuXi our producing doing operations Dr. technical at important at scale partners carbohydrate
success so ahead it Let key turn over accomplishments Brad go ahead the that of are program. me some of to now the please. continued go this to Brad critical highlight to manufacturing and
